Diabetic nephropathy is the leading cause of end-stage renal disease. It is pathologically characterized by the accumulation of extracellular matrix in the mesangium, of which the main component is a1/a2 type IV collagen (Col4a1/a2). Recently, we identified Smad1 as a direct regulator of Col4a1/a2 under diabetic conditions in vitro. Here, we demonstrate that Smad1 plays a key role in diabetic nephropathy through bone morphogenetic protein 4 (BMP4) in vivo. Smad1-overexpressing mice (Smad1-Tg) were established, and diabetes was induced by streptozotocin. Nondiabetic Smad1-Tg did not exhibit histological changes in the kidney; however, the induction of diabetes resulted in an ∼1.5-fold greater mesangial expansion, consistent with an increase in glomerular phosphorylated Smad1. To address regulatory factors of Smad1, we determined that BMP4 and its receptor are increased in diabetic glomeruli and that diabetic Smad1-Tg and wild-type mice treated with a BMP4-neutralizing antibody exhibit decreased Smad1 phosphorylation and ∼40% less mesangial expansion than those treated with control IgG. Furthermore, heterozygous Smad1 knockout mice exhibit attenuated mesangial expansion in the diabetic condition. The data indicate that BMP4/Smad1 signaling is a critical cascade for the progression of mesangial expansion and that blocking this signal could be a novel therapeutic strategy for diabetic nephropathy.
Diabetic nephropathy is a life-threatening complication of diabetes and the leading cause of end-stage renal disease (1) . The structural features of diabetic nephropathy include thickening of the glomerular basement membrane (GBM) and mesangial matrix expansion (2, 3) . Mesangial matrix expansion is pathologically important because it leads to glomerulosclerosis accompanied by various tubulointerstitial damages and subsequent nephron loss (4, 5) . In addition, the severity of mesangial matrix expansion is clinically important because it is closely associated with the decline of the glomerular filtration rate (6) .
Mesangial matrix expansion is characterized by increased amounts of extracellular matrix (7) , particularly a1/a2 type IV collagen (Col4a1/a2) (8) . Although various peptides or growth factors are shown to mediate the regulation of this key component, the protein responsible for its direct regulation remains to be determined.
Because various injuries of epithelial, endothelial, and mesangial cells converge on the accumulation of Col4a1/a2 in the mesangium, mesangial cells presumably play a central role for the regulation of Col4a1/a2, even if they are not the primary target of injury (9) . Therefore, we attempted to elucidate the direct regulation of Col4a1/a2 under diabetic conditions and demonstrate that Smad1 can transcriptionally regulate Col4a1/a2 in the presence of advanced glycation end products in mesangial cells (10) .
Smad1 is an intracellular molecule originally cloned as a signal transducer of the transforming growth factor (TGF)-b superfamily (11) . In response to these stimuli, Smad1 is phosphorylated at the COOH-terminal SSXS motif followed by accumulation in the nucleus where it regulates the transcription of specific target genes (12) . In vivo, Smad1 is essential for the development of the kidney (13) , but it is not detected in adult murine glomeruli (14) . Previously, we reported that Smad1 is induced and phosphorylated by advanced glycation end products and binds to the promoter of Col4a1/a2, thus upregulating its transcriptional activity in mesangial cells (10) . We also found that Smad1 is highly expressed in human diabetic glomeruli and that glomerular expression of Smad1 is closely correlated with the severity of mesangial matrix expansion in a rodent model of diabetic nephropathy (15) . However, the functional role of Smad1 in diabetic nephropathy in vivo remains unknown.
To this end, we sought to demonstrate that transgenic mice overexpressing Smad1 can accelerate mesangial matrix expansion under diabetic conditions and to identify a regulatory factor of Smad1. We also focused on bone morphogenetic proteins (BMPs) because they are potent stimulators of Smad1. Of note, we demonstrate that BMP4 is increased in diabetic glomeruli, so to prove the involvement of BMP4 in diabetic nephropathy, we treated diabetic mice with an anti-BMP4 antibody and demonstrate that the neutralization of BMP4 prevents the phosphorylation of Smad1, accumulation of Col4a1/a2, and mesangial expansion in both diabetic Smad1 transgenic (Smad1-Tg) mice and their littermates.
RESEARCH DESIGN AND METHODS

Generation of SMAD-Overexpressing Mice
All animal experiments in this study were performed in accordance with institutional guidelines, and the review board of Kyoto University granted ethical permission. The pCAGGS-SMAD1 vector was constructed by inserting human SMAD1 cDNA into the mammalian expression vector pCAGGS (provided by J. Miyazaki, Osaka University). Although a previous report indicated that this promoter could be transactivated in glomerular epithelial cells (16) , another report showed that the transgene under this promoter is expressed ubiquitously in glomeruli (17) ; therefore, it could still work in mesangial cells. Transgenic mice expressing SMAD1 were generated as described (18) . Integration of the transgene into host genome was confirmed by Southern blot analysis of DNA using a 32 P-labeled SMAD1 cDNA fragment as a probe (Fig. 1A) .
Generation of Inducible Smad1-Tg Mice
To generate inducible Smad1-Tg mouse lines, we used the tamoxifen-regulated Cre-loxP system (TaconicArtemis GmbH, Köln, Germany). This system consists of two transgenes. The first transgene is the inducible Smad1 expression cassette pMacII-floxed GFP pA-BMP4 using expression vector pMacII consisting of a cytomegalovirus enhancer and mouse b-actin promoter ( Supplementary Fig. 2A ). The second transgene is a construct for the expression of a fusion protein of mutated murine estrogen receptor (Mer) and Cre recombinase (MerCreMer [MCM]), with the pCAGGS vector ( Supplementary Fig. 2A) . MCM cDNA was a gift from M. Reth (Max Planck Institute of Immunobiology and Epigenetics) (19) . Each transgene was microinjected into the pronuclei of C57BL/6J fertilized eggs to create a transgenic mouse line. For induction of SMAD1 gene expression, 8-week-old transgenic mice were fed a diet containing tamoxifen citrate 400 mg/kg.
Induction of Diabetes
Diabetes was induced in 8-week-old mice by injecting streptozotocin (STZ) 50 mg/kg i.p. (Sigma, St. Louis, MO) for 5 consecutive days. Control animals received 0.1 mmol/L sodium citrate buffer (pH 4.5) alone.
Tissue Preparation
The right-side kidney was divided into fragments, each of which was fixed with Carnoy solution, neutral buffered formalin, and 2% glutaraldehyde or was frozen immediately in optimal cutting temperature compound.
Antibody Preparation
The recombinant human BMP4 peptide was purchased from R&D Systems (Minneapolis, MN). For immunization with the peptide, 6-week-old mice were injected subcutaneously with 50 mg conjugated peptide once a week for 4 weeks followed by an interval of 2 weeks. Three days after final immunization, spleen cells were harvested for production of hybridomas to recombinant human BMP4. Monoclonal antibodies were generated using established procedures.
Protocol for the Treatment With a BMP4-Neutralizing Antibody in Mice
Ten milligrams/kilogram of neutralizing anti-BMP4 antibody was injected subcutaneously into each group of mice once every 2 weeks from 24 until 36 weeks after the induction of diabetes. As a negative control, mouse IgG (MP Biomedicals, Solon, OH) was injected at the same time points.
Renal Histology and Morphometric Analyses
Two-micrometer sections embedded in paraffin were collected through the largest axial section and stained with periodic acid silver methenamine (PASM). To quantify mesangial expansion, all tissues were sectioned and stained by one professional pathology technician (H. Uchiyama, Taigenkai Hospital) to control the thickness of sections and the intensity of silver staining of the individual slides. Sections were further coded and read by an observer (M.A.) blinded to the experimental protocol applied (15) .
Electron Microscopy and Measuring GBM Thickness
Portions of the cortex were fixed in 2% glutaraldehyde and postfixed in 1% osmic acid. After embedding, ultrathin sections were stained (20) . The average GBM thickness was measured using Image-Pro Plus software (Media Cybernetics, Bethesda, MD).
Immunohistochemistry
Kidneys were processed as previously described (15) . The primary antibodies used in this experiment are listed in Figure 1 -Smad1-overexpressing mice exhibit severe glomerular injuries after the induction of diabetes. A: Schematic structure of the transgene. The transgene construct carried a chicken b-actin promoter with a cytomegalovirus (CMV) enhancer, rabbit b-globin intron, 1.4-kb human Smad1 cDNA, and rabbit b-globin poly(A). B: Southern blot analysis of genomic DNA extracted from the mouse tail and digested with EcoRI. The 0.9-and 1.4-kb transgenes ( ) were detected in line 59 using a cDNA probe (heavy line in A). The indicates the genomic Smad1. C: Northern blot analysis of Smad1 mRNA in whole kidney of WT and Smad1-Tg mice. The Smad1 mRNA from the transgene is ;1.4 kb ( ), which is smaller than the endogenous transcript (3.3 kb, ). Transgene-specific signals were detected in the kidney of Smad1-Tg#59 and Smad1-Tg#60 mice. Smad1-Tg#32 was the nonexpression line. D: Western blot analysis of Smad1 protein from various tissues of Smad1-Tg mice. The top two panels show blots using an anti-Smad1 antibody that detects both human and mouse Smad1. The bottom two panels show blots using an anti-human Smad1-specific antibody. The transgene was expressed mainly in muscle, heart, and testis. The vertical dividing lines between lanes 2 and 3 and lanes 6 and 7 indicate where irrelevant lanes were deleted from the final image. E: Representative Western blot analysis and bar graph quantification of proteins isolated from the glomeruli in WT (n = 4) and Smad1-Tg (n = 4) mice. Glomeruli isolation was performed using DynaBeads as described in the RESEARCH DESIGN AND METHODS. b-Actin was used as an internal control. *P < 0.05 vs. WT. F: Immunohistochemistry of total Smad1 in the glomerulus. Smad1 was clearly detected in the glomerulus of Smad1-Tg mice and was mainly localized in the mesangial area (middle panel). The right panel is the kidney section of Smad1-Tg mice stained as a control. Sections were counterstained with hematoxylin solution. rSmad1, recombinant Smad1 protein. G: Representative views by light microscopy of the kidney from nondiabetic non-Tg (top left), nondiabetic Smad1-Tg#59 (top right), diabetic non-Tg (bottom left), and diabetic Smad1-Tg#59 (bottom right) mice 36 weeks after STZ treatment. Scale bar = 100 mm (PASM staining, original magnification 3400). H: Mesangial matrix fraction 36 weeks after STZ treatment in each group of mice. Glomerular surface area and PASM-positive area were determined as described in RESEARCH DESIGN AND METHODS. The mesangial sclerotic fraction is reported as the percentage of mesangial matrix area per total glomerular surface area. n = 6 in nondiabetic WT mice, n = 6 in nondiabetic Smad1-Tg#59 mice, n = 10 in STZ-induced diabetic WT mice, n = 10 in STZ-induced diabetic Smad1-Tg#59 mice. Comparisons were made using twoway ANOVA followed by Tukey HSD test. The results indicate significant main and interaction effects for genotype and for diabetes. Data are mean 6 SD. #P < 0.05 vs. nondiabetic mice of the same genotype; *P < 0.05 vs. diabetic WT mice of the same diabetic condition. I: Urinary albumin excretion (UAE) after the induction of diabetes in Smad1-Tg#59 mice and littermates. Data are shown for vehicle-treated non-Tg mice (WT Cont) (n = 6), Smad1-Tg#59 mice (Tg#59 Cont) (n = 6), STZ-treated non-Tg mice (WT STZ) (n = 10), and Smad1-Tg#59 mice (Tg#59 STZ) (n = 10). UAE revealed a marked increase in diabetic Smad1-Tg#59 mice from 24 weeks. Data were logarithmically transformed, and comparisons were made using MANOVA followed by Tukey HSD test for multiple comparisons. Data are mean 6 SD. *P < 0.05 vs. nondiabetic mice of the same genotype at each period compared with the pretreatment period. Ab, antibody; Cont, control. Table 3 . For immunostaining of Smad1, a mouse monoclonal antibody was used as described (21) .
Supplementary
Immunofluorescence Staining and Morphometric Analysis of Glomerular Type IV Collagen Expression
Immunofluorescence staining was performed as described (15) . Fluorescein isothiocyanate-labeled or biotinylated secondary antibody followed by avidin-labeled Alexa Fluor 594 (Molecular Probes, Carlsbad, CA) was applied. For immunofluorescence staining of type IV collagen, 2-mm sections of formalin-fixed paraffin-embedded tissue blocks were used. The antitype IV collagen antibody used in this experiment reacted mainly with mesangium, which includes Col4a1/a2, but not with the GBM, which includes a3/a4/a5 type IV collagen. The immunoreactivity of type IV collagen was quantified as described (15) .
Isolation of Glomeruli
Glomeruli were isolated by DynaBeads (22) . For the quantification of a-smooth muscle actin (aSMA), laser-manipulated microdissection was performed because some of the glomeruli isolated by DynaBeads had the afferent and/or efferent arteriole still attached, which contained abundant aSMA (23).
RNA Isolation
Total RNA was extracted from isolated glomeruli using the guanidinium thiocyanate-phenol-chloroform method (TRIzol reagent, Invitrogen) in 20 mL RNase-free water or from microdissected glomeruli using a PicoPure RNA Isolation Kit (Arcturus, Foster City, CA) in 15 mL elution buffer.
cDNA Preparation and Quantification by Real-Time RT-PCR
For RNA from isolated glomeruli, real-time RT-PCR was performed (24) . Specific primers are listed in Supplementary Table 2 except Col1a2, which was synthesized commercially (ABI primers and probes; Applied Biosystems). For RNA from microdissected glomeruli, the primers and probes were obtained from Applied Biosystems.
Western Blotting
Tissues were homogenized in radioimmunoprecipitation assay buffer and subjected to immunoblotting (25) . The anti-b-actin antibody (#4967), anti-Smad1 antibody reactive only to human or monkey (#9512), and anti-Smad1 antibody reactive to both human and mouse (#9743) were obtained from Cell Signaling Technology (Danvers, MA). The antiphospho-Smad1/5/8 antibody was obtained from Chemicon (Millipore, Billerica, MA). The anti-aSMA antibody was obtained from Sigma. The anti-GAPDH antibody was obtained from BD Biosciences (San Jose, CA).
Plasmid Constructs
The reporter plasmid that contained the Smad1 responsive element (3GC2-Lux) was provided from K. Miyazono (University of Tokyo). The aSMA promoter reporter plasmid (SMA-Luc) contains 219 base pairs of the proximal 59-flanking region of the aSMA gene subcloned into the luciferase reporter vector (Promega, Madison, WI). Expression vectors for wild-type (WT) and mutant Smad1 have been described previously (26) .
Cell Cultures
Murine mesangial cells were established as described previously (25) . After 12-h incubation, cells were starved in DMEM containing 0.5% FCS followed by the stimuli. Treatment with dorsomorphin (Tocris Bioscience, Ellisville, MO), anti-BMP4-neutralizing antibody, or control IgG antibody was performed 30 min before the stimulation.
Plasmid Transfection and Reporter Assay
Mesangial cells or Cos7 cells (1.0 3 10 5 /mL) were seeded into 12-well plates (Nunc). After 6 h, the cells were transfected with 375 ng SMA-Luc or 3GC2-Lux and 37.5 ng pRL-CMV (Promega) along with Smad1-DVD, Smad1-DC expression vector, or a mock vector. Transfection was performed with FuGENE 6 (Roche Diagnostics, Indianapolis, IN). The medium was changed 12 h after transfection to 0.5% FCS in DMEM. Twenty-four hours after medium change, cells were harvested and luciferase activity measured (15) .
Immunostaining of Cultured Cells
Mesangial cells (1.0 3 10 5 /mL) were seeded in chamber slides (Nalge Nunc, Roskilde, Denmark). Twenty-four hours after transfection and medium change, cells were fixed in 4% paraformaldehyde and treated with antiSmad1 antibody at 1:100 (T-20; Santa Cruz Biotechnology, Dallas, TX). An appropriate fluorescein isothiocyanateconjugated secondary antibody was used.
Statistical Analysis
All analyses were performed using JMP 11 software (SAS Institute, Cary, NC). Normal distribution assumptions were verified using the Shapiro-Wilk test. For type II Bmp receptor (BmprII), type I Bmp receptor (Alk3), Smad1, and albuminuria, logarithmically normal distribution assumptions were verified. Analyses were performed using MANOVA for the time course of albuminuria and one-way or two-way ANOVA for other variables followed by Tukey honest significant difference (HSD) test for multiple comparisons. Data are presented as mean 6 SD. P , 0.05 was considered significant.
RESULTS
Establishment of Smad1-Overexpressing Mice
We constructed a transgene consisting of a fragment of the chicken b-actin promoter and human Smad1 cDNA (Fig. 1A) . Transgenic founder lines carrying the human Smad1 transgene were identified by Southern blot analysis (Fig. 1B) . Human SMAD1 mRNA was detected in only two founders (Tg#59 and Tg#60). Moreover, because of their poor fertilizing ability, only one line could be finally established from the male founder (Tg#59) (Fig. 1C) . Western blot analyses for Smad1 revealed that Smad1 from the transgene was mainly expressed in skeletal muscle, heart, and testis and was slightly expressed in whole kidney, whereas endogenous Smad1 was expressed ubiquitously (Fig. 1D) . On the other hand, Smad1 was increased ;50% in Tg mice compared with their WT littermates in isolated glomeruli (Fig. 1E) . Immunohistochemical analysis revealed that Smad1 from the transgene was detected mainly in the mesangial area (Fig. 1F) . To confirm that the Smad1 transgene was expressed in mesangial cells, primary cultures were established from glomeruli isolated from normal 4-week-old Smad1-Tg#59 mice. Smad1 from the transgene was detected in primary cultured mesangial cells from Tg#59 mice (Supplementary Fig. 1A ). We also confirmed no contamination of glomerular epithelial cells in this primary culture from Tg#59 mice by demonstrating that cell lysate from Tg#59 cells did not contain E-cadherin ( Supplementary Fig. 1B ). However, there were no significant histological changes in the kidney between Smad1-Tg#59 mice and their WT littermates. The glomerular density and glomerular surface area were also comparable between the two groups (10.8 6 1.9 vs. 11.3 6 2.2 mm 2 and 1,980 6 290 vs. 1,910 6 260 mm 2 , respectively). Because we could obtain only one line using this construct, we established another line of Smad1-Tg mice with inducible Smad1 expression using the tamoxifenregulated Cre-loxP system (Supplementary Fig. 2A ). The transgene was expressed mainly in epithelial cells (Supplementary Fig. 2B -J) and partly in the mesangial area ( Supplementary Fig. 2K ). After induction by tamoxifen, Smad1 was significantly increased in various tissues, including kidney (Supplementary Fig. 2L ).
The Effect of Smad1 Overexpression on Albuminuria and Mesangial Matrix Expansion After the Induction of Diabetes
To examine the role of Smad1 overexpression in diabetic nephropathy, we induced diabetes by STZ. Body weights, HbA 1c , and blood pressure in diabetic Smad1-Tg mice did not differ from their diabetic littermates (Table 1) .
First, we analyzed mesangial matrix expansion of each group of mice 36 weeks after STZ treatment. Morphometric analysis revealed a significant increase in the mesangial matrix expansion of diabetic Smad1-Tg#59 mice (Fig. 1H ) and inducible Smad1-Tg#5 mice ( Supplementary Fig. 2M ) compared with their diabetic littermates. Histologically, most glomeruli exhibited a widespread increase in PASMpositive material within the mesangium, termed "diffuse lesion" (Fig. 1G) . Diabetic MCM-Tg mice, which did not express the Smad1 transgene, exhibited similar mesangial expansion to their WT littermates (Supplementary Fig. 2M ).
Next, we measured albuminuria in each group of mice. Both WT and Smad-Tg#59 diabetic mice exhibited more albuminuria than nondiabetic mice at 24 weeks, and these increases were sustained through 32 weeks during the experimental period (Fig. 1I) . However, there was no difference in albuminuria levels between WT and Smad1-Tg#59 mice, although diabetic Smad1-Tg#59 mice tended to exhibit slightly more albuminuria than WT mice. Inducible Smad1-Tg#5 also exhibited a tendency toward slightly extended albuminuria relative to their littermates or MCM-Tg mice 32 weeks after the induction of diabetes, but the trend was not statistically significant ( Supplementary Fig. 2N ).
Effects of Smad1 Overexpression on Diabetic Nephropathy
Previously, we reported that Smad1 transcriptionally regulates Col4a1/a2 and other extracellular matrix proteins, such as type I collagen, in vitro (10). Because mesangial matrix expansion was accelerated in diabetic Smad1-Tg mice compared with their diabetic littermates, we quantified the glomerular expression of Col4a1/a2 and Col1a1/a2 in these mice. As shown in Fig. 2A , the glomerular expression of these molecules was increased in diabetic mice compared with nondiabetic mice. Moreover, the expression was significantly increased in diabetic Smad1-Tg mice relative to their diabetic littermates. Immunohistochemistry revealed that these molecules were accumulated mainly in the mesangial area (Fig. 2B) . aSMA is another key molecule in diabetic glomerulopathy and a marker of mesangial phenotypic changes. Therefore, we examined the glomerular expression of aSMA in each group of mice. In diabetic mice, the expression of aSMA was significantly increased after STZ treatment. Of note, Smad1-Tg mice exhibited significant expression of aSMA at the same stage ( Fig. 2A) . Immunohistochemistry revealed that increased aSMA was also localized mainly in the mesangial area (Fig. 2B) . Comparisons were made using two-way ANOVA followed by Tukey HSD test. The results indicate significant main effects for genotype and for diabetes for all factors as well as significant effects for the genotype 3 diabetes interaction with respect to Col1a1, aSMA, phosphorylated Smad1 (pSmad1), and the thickness of GBM. No significant interaction effects were observed with respect to Col4a1/a2, Col1a2, Col4a3, and Smad1. #P < 0.05 vs. nondiabetic mice of the same genotype; *P < 0.05 vs. WT mice in the same diabetic condition. H: Representative immunohistochemistry of pSmad1 in WT and Smad1-Tg#59 mice at 36 weeks with or without STZ treatment. Scale bar = 50 mm. I: Enlarged glomerular image of the box in H. Positive nuclear staining for pSmad1 was localized in the mesangial area (*) and endocapillary area ( ). Sections were counterstained with hematoxylin solution. Note that glomerular parietal cells were negative for pSmad1 ( ). Scale bar = 50 mm. Cont, control; ns, not significant.
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We further investigated the thickness of the GBM by electron microscopy. Diabetic Smad1-Tg mice exhibited significant GBM thickening relative to their diabetic littermates at the same stage ( Fig. 2C and D) . Glomerular expression of Col4a3, a major molecular component of the GBM, was also increased in diabetic Smad1-Tg in parallel with GBM thickening (Fig. 2E) .
Phosphorylation of Smad1 After the Induction of Diabetes in Smad1-Tg Mice
These data demonstrate that the overexpression of Smad1 per se does not exacerbate nephropathy. Smad1 is activated by the phosphorylation of its carboxyl terminus. Therefore, we quantified Smad1 activation by counting cells with positive staining of phosphorylated Smad1. Although glomerular expression of Smad1 was increased in Smad1-Tg mice relative to their littermates (Fig. 2F) , phosphorylated Smad1 was barely detectable in both Smad1-Tg mice and their littermates before STZ treatment. After STZ treatment, however, Smad1 was phosphorylated and translocated into the nucleus in both Smad1-Tg mice and their littermates (Fig. 2G and  H) . Of note, nuclear translocation of phosphorylated Smad1 was more evident in diabetic Smad1-Tg mice Table 2 . n = 6 in nondiabetic WT mice, n = 6 in nondiabetic Smad1-Tg#59 mice, n = 10 in STZinduced diabetic WT mice, and n = 10 in STZ-induced diabetic Smad1-Tg#59 mice. Comparisons were made using two-way ANOVA followed by Tukey HSD test. The results indicate significant main effects for diabetes but no significant main effects for genotype or for the genotype 3 diabetes interaction effects with respect to BMP4, BMPRII, and ALK3. #P < 0.05 vs. nondiabetic mice of the same genotype. B: Representative immunohistochemistry of BMP4 in diabetic Smad1-Tg mice (Tg#59 STZ). Note that the glomerular expression of BMP4 was mainly localized in podocytes ( ). Scale bar = 50 mm. The inset is an enlarged image of the area around an . Sections were counterstained with hematoxylin solution. Scale bar = 25 mm. C: Double immunofluorescent staining for ALK3 with desmin, PDGFRb, or nephrin. Desmin is a marker of mesangial cells or injured podocytes, PDGFRb is a marker of mesangial cells, and nephrin is a marker of podocytes. ALK3 (first row); desmin (second row, left panel), PDGFRb (second row, middle panel), and nephrin (second row, right panel); and merged images (third row) from nondiabetic mice (Tg#59 Cont, left columns) and diabetic mice (Tg#59 STZ, right columns) are presented. Note that ALK3 is hardly detectable or is presumably localized only around the vascular pole of the nondiabetic glomeruli ( ). On the other hand, ALK3 is increased in diabetic glomeruli and colocalized with desmin (third row in left panel) and PDGFRb (third row in middle panel) but not with nephrin (third row in right panel). Cont, control; ns, not significant. Scale bar = 50 mm. than in their littermates (Fig. 2H) and was largely localized in mesangial and/or endocapillary cells (Fig. 2I) .
Diabetic Changes in the Regulatory Factors of Smad1 Phosphorylation
The data demonstrate that Smad1 is phosphorylated under diabetic conditions. BMPs/BMPRs are generally accepted as potent stimulators of Smad1. Among the BMPs, BMP2, -4, and -7 are expressed at various sites in different embryonic stages of renal development (27) (28) (29) . We observed that Bmp7 was abundantly expressed both in nondiabetic and diabetic glomeruli, but there was no difference in its expression between the nondiabetic and diabetic groups of mice (Fig. 3A) . Of note, glomerular expression of Bmp4 was increased approximately twofold after STZ treatment in both WT and Smad1-Tg mice (Fig. 3B) , although Bmp2 was not detected by quantitative RT-PCR (RT-qPCR) from the same aliquot (data not shown). These data suggest that BMP4 is involved in the progression of diabetic nephropathy. BMPs induce Smad1 phosphorylation by forming heterotetrameric , and glomerular accumulation of type IV collagen (D) and improved the glomerular expression of aSMA (E) in both diabetic Smad1-Tg mice and their diabetic littermates. Morphometric analyses were performed as described in RESEARCH DESIGN AND METHODS. To quantify aSMA, mRNA was extracted from isolated glomeruli by laser-manipulated microdissection. The number of mice in each group in this experiment is listed in Table 2 . Comparisons were made using one-way ANOVA followed by Tukey HSD test. #P < 0.05 vs. nondiabetic mice; *P < 0.05 vs. diabetic littermates; **P < 0.05 vs. mice treated with control IgG; §not examined. F: Representative histological views after treatment with the BMP4 antibody. The neutralizing anti-BMP4 antibody was injected subcutaneously into each group of mice once every 2 weeks from 20 to 36 weeks after diabetes induction. PASM staining results are presented. WT (top row) and Smad1-Tg (bottom row) mice were nondiabetic and treated with control IgG (left column); diabetic and treated with control IgG (middle column); or diabetic and treated with anti-BMP4 antibody (right column). Sections were counterstained with hematoxylin solution. Scale bar = 50 mm. G: Urinary excretion of albumin (UAE) in each group of mice. The number of mice in each group used in this experiment is listed in Table 2 . Data were logarithmically transformed, and comparisons were made using one-way ANOVA followed by Tukey HSD test. #P < 0.05 vs. nondiabetic mice of the same genotype. Cont, control; ns, not significant. complexes with two major types of membrane-bound serine/threonine kinase receptors: the type I ALK receptors and the type II receptors (30) . In vitro binding assays suggest that ALK3/6 are type I receptors for BMP4 (31, 32) . Therefore, we examined the glomerular expression of BMPRII, Alk3, and Alk6 in these mice. The glomerular expression of BmprII and Alk3 but not Alk6 was increased after STZ treatment. Next, we studied the localization of BMP4 and ALK3 by immunohistochemistry. In nondiabetic mice, BMP4 was barely detected in the glomeruli (data not shown). In contrast, 36 weeks after diabetes induction, BMP4 was extensively expressed in the podocytes and partly in the mesangium (Fig. 3B) . Double immunostaining for ALK3 and desmin, platelet-derived growth factor (PDGF) receptor b (PDGFRb), or nephrin revealed that increased ALK3 in diabetic glomeruli was mainly localized in the mesangium (Fig. 3C ). These data suggest that BMP4/ ALK3/Smad1 signaling contributes to the progression of diabetic nephropathy.
Neutralizing BMP4 Ameliorates the Exacerbation of Glomerular Injuries in Diabetic Mice
To further delineate the role of BMP4 in the development of diabetic nephropathy, we administered a neutralizing antibody against BMP4 to both diabetic Smad1-Tg mice and their diabetic littermates. First, we evaluated the specificity of the neutralizing activity of the antibody using an assay measuring Smad1 phosphorylation in mesangial cells induced by BMPs and TGF-b. The addition of the antibody completely inhibited the phosphorylation of Smad1/5/8 induced by BMP4 but not by BMP2, BMP7, or TGF-b (Fig. 4A) , indicating its specificity. Next, we administered the neutralizing antibody or control IgG to each group of mice ( Table 2 ). The administration of the neutralizing antibody attenuated the nuclear translocation of phosphorylated Smad1 (Fig. 4B) , ameliorated the glomerular accumulation of type IV collagen (Fig. 4D) , and inhibited mesangial matrix expansion (Fig. 4C and F) in both diabetic Smad1-Tg mice and littermates. Furthermore, RTqPCR of RNA from glomeruli isolated by laser-manipulated microdissection revealed that treatment with the BMP4-neutralizing antibody also improved glomerular expression of aSMA in both diabetic Smad1-Tg mice and littermates (Fig. 4E) . However, the BMP4-neutralizing antibody did not have any effect on albuminuria (Fig. 4G) .
Role of BMP4 in Mesangial Cell aSMA Expression
In this study, we demonstrate that overexpression and subsequent phosphorylation of Smad1 results in an increase in the glomerular expression of aSMA, whereas the inhibition of Smad1 phosphorylation using an anti-BMP4 antibody leads to the improvement of glomerular expression of aSMA. To further elucidate the relationship between Smad1 phosphorylation and aSMA, we generated Smad1 mutants: a constitutively active mutant in which two serine residues at the carboxyl termini were substituted with aspartic acid (Smad1-DVD) (26) and a dominant negative mutant in which the carboxyl termini were lacking (Smad1-DC) (Fig. 5A) . The expression of Smad1-DVD increased the transcriptional activity of 3GC2-Lux, a Smad1-dependent reporter, whereas the expression of Smad1-DC did not (Fig. 5B) . In mesangial cells, Smad1-DVD was localized in the nuclei, whereas Smad1-DC was localized mainly in the cytoplasm (Fig. 5C ). Therefore, we asked whether the transcriptional activity of aSMA is modulated by the constitutive activation of Smad1 in mesangial cells. As expected, the expression of Smad1-DVD but not Smad1-DC increased the transcriptional activity of aSMA in mesangial cells (Fig. 5D) . Finally, we examined whether dorsomorphin, a small molecule inhibitor of BMP signaling (33) , can affect the expression of aSMA by inhibiting the phosphorylation of Smad1 in mesangial cells. As shown in Fig. 5E and F, BMP4 induced the phosphorylation of Smad1 along with increased aSMA expression, which was blocked by dorsomorphin. These data indicate that BMP4 mediates aSMA expression through the phosphorylation of Smad1 in mesangial cells.
Heterozygous SMAD1 Knockout Mice Exhibit Attenuated Mesangial Sclerosis in Diabetes
We further investigated whether the reduction of Smad1 expression improves diabetic glomerular changes by using heterozygous SMAD1 knockout (KO) mice, which were provided from Anita B. Roberts (National Cancer Institute, Bethesda, MD) (34) . After the induction of diabetes, body weights, blood pressure, and HbA 1c in diabetic SMAD1 heterozygous KO mice did not differ from diabetic WT mice (Supplementary Table 4 ). The glomerular expression of Smad1 was reduced by ;30% in both diabetic and nondiabetic SMAD1 heterozygous KO mice (Fig. 6A ). We observed a partial attenuation of albuminuria (Fig. 6B ) and mesangial matrix expansion ( Fig. 6C and D) along with improvement of the glomerular expression of Col4a1/a2 and Col1a1/a2 (Fig. 6E ) in diabetic SMAD1 Note that Smad1-DVD was detected in the nucleus, whereas Smad1-DC was detected mainly in the cytoplasm. D: Smad1-DVD increased the transcriptional activity of aSMA in mesangial cells. Each Smad1 mutant vector was transfected with mouse aSMA-promoter luciferase construct into mesangial cells. After 24 h, the luciferase activities of cell lysate were measured as described in RESEARCH DESIGN AND METHODS. Data are mean 6 SD of triplicate determinations. *P < 0.05 vs. mock vector; #P < 0.05 vs. Smad1-DVD. E and F: BMP4 increases aSMA in mesangial cells by phosphorylation of Smad1. Mesangial cells were preincubated with dorsomorphin 1 mmol/L for 30 min followed by stimulation with BMP4 25 ng/mL. Twentyfour hours after stimulation, cells were harvested. One representative blot is presented in E, and the mean optical densitometry of aSMA/ b-actin from three independent experiments is presented in F. *P < 0.05 vs. control without dorsomorphin or BMP4; #P < 0.05 vs. BMP4 stimulation without dorsomorphin. pSmad, phosphorylated Smad.
heterozygous KO mice compared with diabetic WT mice. These data suggest that Smad1 is a critical determinant for the development of diabetic nephropathy.
DISCUSSION
In this study, we demonstrate that Smad1 plays a critical role in the development of diabetic nephropathy. Smad1 is the only molecule shown in vivo to be a direct regulator of Col4a1/a2; therefore, it seems reasonable to consider Smad1 or its modifier as therapeutic targets for diabetic nephropathy. In this regard, BMP4 could be a potential candidate. We reported that heterozygous BMP4 KO mice exhibit attenuated diabetic nephropathy (18) . However, because these mice display renal abnormalities (35) , this attenuation might be partly due to the effect of the congenital kidney anomalies. Therefore, in the present study, we used a more physiological method for modulating BMP4 action using the BMP4-blocking antibody and demonstrated that the inhibition of BMP4 ameliorates diabetic glomerular injuries. Although BMP7 is known to protect against diabetic nephropathy, the data suggest that BMP4 could aggravate diabetic nephropathy. BMP4 could have several distinct roles from BMP7 in its structure and function. First, BMP4 has only 58% homology in peptide sequence to BMP7. Second, the functional targets differ between BMP4 and BMP7 during kidney development. For example, BMP4 promotes glomerulogenesis, but BMP7 does not. On the other hand, BMP7 but not BMP4 contributes Figure 6 -Heterozygous SMAD1 KO mice exhibit attenuated mesangial sclerosis in diabetes. A: Quantification of the Smad1 mRNA expression in the glomeruli 36 weeks after the induction of diabetes by STZ treatment. Comparisons were made using two-way ANOVA followed by Tukey HSD test. The results indicate significant main effects for genotype and for diabetes but no significant interaction effects. #P < 0.05 vs. nondiabetic mice of the same genotype; *P < 0.05 diabetic WT vs. KO mice. B: Urinary albumin excretion (UAE) 36 weeks after STZ treatment in SMAD1 heterozygous KO mice and littermates. Comparisons were made using two-way ANOVA followed by Tukey HSD test. The results indicate significant main effects and interaction effects for genotype and diabetes. #P < 0.05 vs. nondiabetic mice of the same genotype; *P < 0.05 diabetic WT vs. KO mice. C: Representative light microscopy images of the kidney from nondiabetic WT (top left), nondiabetic SMAD1 heterozygous KO (top right), diabetic WT (bottom left), and diabetic SMAD1 heterozygous KO (bottom right) mice 36 weeks after STZ treatment. Scale bar = 100 mm (PASM staining, original magnification 3400). D: Mesangial matrix fraction 36 weeks after STZ treatment in each group of mice. Comparisons were made using two-way ANOVA followed by Tukey HSD test. The results indicate significant main and interaction effects for genotype and diabetes. #P < 0.05 vs. nondiabetic mice in the same genotype; *P < 0.05 diabetic WT vs. KO mice. E: Col4a1/a2 and Col1a1/a2 mRNA by RT-qPCR in isolated glomeruli of the kidney 36 weeks after STZ treatment. Comparisons were made using two-way ANOVA followed by Tukey HSD test. The results indicate significant main effects for genotype and for diabetes in all factors as well as significant interaction effects with respect to Col4a1 but no significant interaction effects with respect to Col4a2 and Col1a1/a2. #P < 0.05 vs. nondiabetic mice of the same genotype; *P < 0.05 diabetic WT vs. KO mice. In A, B, D, and E, n = 5 in nondiabetic WT mice, n = 4 in nondiabetic SMAD1 heterozygous KO mice, n = 6 in diabetic WT mice, and n = 5 in diabetic SMAD1 heterozygous KO mice. Data are mean 6 SD. Cont, control; ns, not significant.
to mesenchymal survival (36) . Finally, the downstream target of BMP4 is Smad1 in mesangial cells, as demonstrated in the present study, whereas the downstream target of BMP7 in mesangial cells is Smad5 (37) . Thus, we suggest that each BMP has its own function and signaling targets in kidney development and disease progression.
It remains to be determined whether BMP4/Smad1 signaling is specific for diabetic nephropathy. We previously reported increased glomerular expression of BMP4/Smad1 in another diabetic mouse model (38) and identified PDGF-b as another activator of Smad1 in mesangial cells through Src in murine experimental glomerulonephritis (39) . Smad1 also operates during chronic stages of fibrosis in scleroderma (40). Thus, we speculate that the Smad1 signaling is a common pathway among various glomerular injuries and in organ fibrosis. To determine the specificity of BMP4 in diabetic nephropathy, the glomerular expression of BMP4 should be tested in other disease models in future experiments.
In this study, albuminuria did not reflect mesangial expansion in BMP4 antibody-treated diabetic mice and diabetic Smad1-Tg mice, although diabetic Smad1 heterozygous KO mice exhibited slightly improved albuminuria. The mechanisms responsible for these results remain unknown. Previous reports have indicated that albuminuria is not correlated with the severity of mesangial expansion in incipient diabetic nephropathy both in humans (41) and in a rodent model (15) . Treatment with an anti-TGF-b antibody does not attenuate albuminuria in db/db mice despite its beneficial effects on glomerular matrix expansion (42) . These data suggest that distinct mechanisms may underlie albuminuria and mesangial matrix expansion in diabetic nephropathy.
In conclusion, this study of Smad1-overexpressing mice reveals that both the induction and the phosphorylation of Smad1 play critical roles in the development of diabetic glomerulopathy in vivo. BMP4 might be responsible for the phosphorylation of Smad1 and represents a novel therapeutic target for diabetic nephropathy.
